Andy specialises in pharmaceuticals and nutrition. He has experience prosecuting patent applications in many major jurisdictions and spends much of his time involved in EPO opposition and appeal proceedings representing innovative multi-national clients. Andy has a particular interest in maximising protection for marketed pharmaceutical products and has helped coordinate a number of European-wide supplementary protection certificate (SPC) filing programs.
Prior to joining E+F, Andy ran a scientific programme at the MRC and he retains an Honorary Senior Lectureship at UCL. Andy has practical experience in a full range of pre-clinical drug discovery including assay development, high-throughput screening, lead development and in vivo proof-of-concept models. He is a Chartered Chemist and has published articles in a variety of scientific journals including Nature, Science and PNAS.
PhD – Chemistry – University of Birmingham
BSc – Chemistry – University of Birmingham
Prion protein as a toxic acceptor of amyloid-β oligomers; S. Purro, A. Nicoll, J. Collinge (2018) Biol. Psychiatry, 83, 358;
G-quadruplex-binding small molecules ameliorate C9orf72 FTD/ALS pathology in vitro and in vivo; R. Simone, et al. (2018) EMBO Mol. Med., 10, 22.
Evidence for human transmission of Aβ pathology and cerebral amyloid angiopathy; Z. Jaunmuktane, S. Mead, M. Ellis, J. Wadsworth, A. Nicoll, et al. (2015) Nature, 525, 247;
Identification of a compound which disrupts binding of Aβ to PrP using a novel fluorescence-based assay; E. Risse, A. Nicoll et al. (2015) J. Biol. Chem., 290, 17020;
C9orf72 repeat expansions cause neurodegeneration in Drosophila through arginine-rich proteins; S. Mizielinska, et al. (2014) Science, 345, 1192;
Peripheral administration of a humanised anti-PrP antibody blocks Alzheimer’s disease Aβ synaptotoxicity; I. Kylubin*, A. Nicoll* et al. (2014) J. Neurosci., 34, 6140;
mGlu5 receptors and cellular PrP mediate Aβ-facilitated synaptic long-term depression in vivo; N.-W. Hu, A. Nicoll et al. (2014) Nat. Commun., 5, 3374;
Aβ nanotubes are associated with PrP dependent synaptotoxicity; A. Nicoll et al. (2013) Nat. Commun., 4, 2416;
Interaction between PrP and toxic Aβ assemblies can be therapeutically targeted at multiple sites; D. Freir*, A. Nicoll* et al. (2011) Nat. Commun., 2, 336;
A pharmacological chaperone for the structured domain of human PrP; A. Nicoll* et al. (2010) Proc. Natl. Acad. Sci. U.S.A., 107, 17610;
Designed high affinity Cu2+-binding α-helical foldamer; A. Nicoll, D. Miller, K. Futterer, R. Ravelli, R. Allemann (2006) J. Am. Chem. Soc., 128, 9187.